Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5890023 | 0.85 | ALDH1A1 (0.47) | CNR1CNR2TSHRGAAALDH1A1 | |
| SCHEMBL4963369 | 0.84 | CYP19A1 (0.40) | CNR1CNR2CYP19A1TSHRMAPK1 | |
| SCHEMBL6828614 | 0.82 | ALDH1A1 (0.47) | CNR1CNR2TSHRMAPK1GAA | |
| SCHEMBL5889950 | 0.79 | MRGPRX4 (0.50) | TSHRMAPK1VDRALDH1A1KDM4E | |
| SCHEMBL6905585 | 0.79 | CYP19A1 (0.44) | CNR1CNR2CYP19A1VDRKDM4E | |
| SCHEMBL6826195 | 0.78 | ESR1 (0.52) | CNR1CNR2AR | |
| SCHEMBL5889681 | 0.77 | SMPD1 (0.47) | MAPK1ALDH1A1KDM4EKMT2A | |
| SCHEMBL6086103 | 0.77 | FFAR1 (0.46) | CNR1CNR2CYP19A1VDRALDH1A1 | |
| SCHEMBL6826320 | 0.77 | ALDH1A1 (0.42) | MAPK1GAAALDH1A1KMT2A | |
| SCHEMBL8579692 | 0.76 | VDR (0.44) | CNR1CNR2CYP19A1MAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040230073-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | AJINOMOTO CO., INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20020132032-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | AJINOMOTO CO., INC. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219633-A1 | PROCESS FOR PRODUCING ASPARTAME DERIVATIVE, CRYSTALS THEREOF, NOVEL PRODUCTION INTERMEDIATES THEREFOR AND PROCESS FOR PRODUCING THE INTERMEDIATE | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230073-A1 | Process for production of aspartame derivative, crystal thereof, novel production intermediate therefor, and process for production of intermediate thereof | IAPP, DPP4, SI | CNR1 4741/4885CNR2 4776/4885CYP19A1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.